;

TAPI at CPhI China 2019 - supporting local and global efforts

Looking to expand your market presence in China, or to take your pharma operation global? TAPI has all answers at CPhI China!

By Tingting Zhou, Assoc Dir TAPI Sales, Sales (TAPI Hangzhou)

 

Essential market insights, the latest local and global regulatory updates, and an exclusive preview of our new portfolio – just a few of the reasons to visit Booth W2B20 at CPhI China in Shanghai, where TAPI's top sales and regulatory professionals are always on hand to meet customers and answer all your questions about the future of this thriving market.

Regulatory Affairs Events CPhI

CPhI China is a real highlight of the industry calendar, offering more than 70,000 pharmaceutical professionals a can't-miss opportunity to meet key decision makers and stay abreast of all the latest market developments. This year, the intensive three-day event will be held from June 18 to 20 at the SNIEC in Shanghai, and naturally our local team, backed by regulatory affairs experts, will be attending to welcome current and potential customers from throughout China, the Asia Pacific region, and beyond.

 

Visit our team at Booth W2B20 where, for the eighth consecutive year, TAPI will be unveiling new pipeline products for the Chinese market and giving attendees the invaluable opportunity to consult a leading regulatory expert on National Medical Product Administration (NMPA) issues, as well as global regulation for key markets like the USA.

 

End-to-end service is just the beginning

 

China is the world's second largest pharma market, and TAPI has firmly established its leading position as an API supplier thanks to an extensive portfolio, global presence, high quality standards, and second-to-none API expertise. For TAPI, the product is only the beginning. We offer end-to-end solutions that encircle each product with comprehensive related services, added value, and full regulatory support, making us the optimal partner throughout the entire API lifecycle: R&D, submission, launch, and commercial stages.

 

TAPI at CPhI China 2019

Introducing our exciting pipeline products

CPhI is the perfect venue to unveil our new pipeline products, with our portfolio presented for your perusal in our meeting room. These new APIs, give our customers the opportunity to develop the first generics in the market. Of course, all our products are on track for approval via the official NMPA process, as per local market regulations, so you can always be confident when using TAPI products for your development needs. The status of each product can be monitored via the CDE website.

 

Some of our new products intended for the Chinese market include:

 

  • Linagliptin
  • Cinacalcet
  • Desvenlafaxine Succinate
  • Sugammadex Sodium
  • Rotigotine Form II
  • Edoxaban Tosylate
  • Sacubitril-Valsartan
  • Haloperidol Decanoate
  • Ezetimibe
  • Duloxetine

 

TAPI’s pipeline products:

  • Linagliptin
  • Cinacalcet
  • Desvenlafaxine Succinate
  • Sugammadex Sodium
  • Rotigotine Form II
  • Edoxaban Tosylate
  • Sacubitril-Valsartan
  • Haloperidol Decanoate
  • Ezetimibe
  • Duloxetine
  • Ulipristal
  • Ixazomib Citrate
  • Venetoclax
  • Fingolimod
  • Olodaterol
  • Solifenacin
  • Carfilzomib
  • Bortezomib
  • Azacitidine
  • Paliperidone Palmitate

 

 

If you would like to learn more about any or all of these products, the TAPI China team will be available to fill you in on every detail – contact us here to schedule your meeting.

 

Your regulatory partner for hassle-free approval

 

We expect that NMPA's stringent DMF requirements will be a hot topic for CPhI attendees. And, as always, we can assure you that TAPI's rigorous quality standards and industry-leading compliance, supported by extensive documentation, offer our customers a vital competitive edge.

Our special guest this year will be regulatory affairs manager Ms. Jay Chen – a highly-experienced veteran of China's pharmaceutical market who can also offer invaluable insights for local companies seeking to go global to markets such as the U.S. market.

Jay will be on hand to review NMPA and international regulatory affairs from every angle, helping to clarify complex issues, and streamline your application and approval processes. Make sure you book a meeting with Jay as early as possible, as only a few spots are left. Simply contact us here or reach out to your account manager to arrange a convenient timeslot.

We look forward to seeing you all at CPhI, where we can discuss potential collaborations and ways to take your TAPI experience to the next level, helping you achieve your competitive goals in the short and long term.

 

Our cGMP-compliant API sterilization service is now ready for orders

 

We are also very proud to introduce the innovative new sterilization service TAPI will be supplying to Chinese customers from Q3 2019. API sterilization is a key consideration for many customers, so we are delighted to add this service to our best-in-class resources. You will be pleased to learn that our state-of-the-art sterilization facility uses the aseptic filtration technique, which avoids damaging the API (essential for sensitive products) or forming new impurities. For more details, just visit Booth W2B20 to examine your API sterilization needs with our experts.

 

About the author

TingTing Zhou, Associate Director of TAPI Sales, China. TingTing has been heading the China office for the last decade, and is considered as an expert in imported APIs, her vast experience with customers in China and knowledge on the NMPA regulations is bringing huge value for customers interested in TAPI’s products in the market.